QUEBEC, Oct. 28, 2015 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that the OptoWire, its guidewire to measure Fractional Flow Reserve ("FFR"), which is designed to optimize and guide treatment in patients with coronary heart disease, has been used as a diagnostic tool by cardiologists in 1,000 patients, marking a milestone for the Company.
Opsens has initiated a pre-marketing phase for its FFR products in Japan, Europe, Canada and the United States during 2015. As part of this pre-commercialization, the OptoMonitor and OptoWire were distributed to hospitals and cardiologists recognized for their expertise in FFR. Opsens' FFR products have received praise and aroused the enthusiasm of users, including the founding fathers of FFR, Drs. Bernard de Bruyne and Nico Pijls. Opsens FFR products were also used in many cases broadcasted live.
"The successful use of the OptoWire in 1,000 patients marks an important step towards large-scale commercialization. The speed with which the pre-marketing phase took place, considering the relatively high number of procedures completed, shows the acceptance and relevance of the OptoWire and OptoMonitor within the interventional cardiology community. We anticipate that the growth will accelerate in the coming quarters now that this stage has been successfully reached, "said Louis Laflamme, President and Chief Executive Officer of Opsens Inc.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of Fractional Flow Reserve ("FFR") in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.
For further information: Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996; Louis Laflamme, CPA, CA, President and Chief Executive Officer, 418.682.9996